Short answer
Parabilis Medicines Inc (PBLS) filed an 8-K current report with the SEC on September 2, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Chief Medical Officer Fawzi Benzaghou, M.D. departing effective September 30, 2026.
Parabilis Medicines Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Chief Medical Officer Fawzi Benzaghou, M.D. departing effective September 30, 2026
- Mutual transition indicates an agreed separation rather than reported involuntary termination
- Severance payable under Benzaghou’s employment agreement, creating a cash obligation
- CMO transition may affect clinical development leadership and program execution continuity
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Parabilis Medicines Inc 8-K filings
Get the next PBLS 8-K as it lands
Follow PBLS for push alerts, or ask the research agent what this filing means.